{"id":"https://openalex.org/W2288922809","doi":null,"title":"Venlafaxine Discontinuation Syndrome: Prevention and Management","display_name":"Venlafaxine Discontinuation Syndrome: Prevention and Management","alternate_titles":[],"publication_year":2015,"publication_date":"2015-11-01","ids":{"openalex":"https://openalex.org/W2288922809","mag":"2288922809"},"language":"en","primary_location":{"id":"mag:2288922809","doi":null,"is_oa":false,"landing_page_url":"https://www.questia.com/library/journal/1G1-435541400/venlafaxine-discontinuation-syndrome-prevention-and","pdf_url":null,"source":{"id":"https://openalex.org/S2764520953","display_name":"Current psychiatry","issn_l":"1537-8276","issn":["1537-8276"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4322696809","host_organization_name":"Frontline Medical Communications","host_organization_lineage":["https://openalex.org/P4322696809"],"host_organization_lineage_names":["Frontline Medical Communications"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Current psychiatry","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2288922809"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080440532","display_name":"Awais Aftab","orcid":"https://orcid.org/0000-0002-3515-3993","observed_orcids":["https://orcid.org/0000-0002-3515-3993"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Awais Aftab","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5080440532"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1815,"has_fulltext":false,"cited_by_count":2,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.48482627,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":93},"biblio":{"volume":"14","issue":"11","first_page":"64","last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9771000146865845,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9771000146865845,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11921","display_name":"Electroconvulsive Therapy Studies","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venlafaxine","display_name":"venlafaxine","score":0.9869999885559082},{"id":"https://openalex.org/keywords/discontinuation-syndrome","display_name":"discontinuation syndrome","score":0.8640000224113464},{"id":"https://openalex.org/keywords/antidepressant-discontinuation","display_name":"antidepressant discontinuation","score":0.8159999847412109},{"id":"https://openalex.org/keywords/serotonin-norepinephrine-reuptake-inhibitors","display_name":"serotonin-norepinephrine reuptake inhibitors","score":0.9850000143051147},{"id":"https://openalex.org/keywords/desvenlafaxine","display_name":"desvenlafaxine","score":0.9470000267028809},{"id":"https://openalex.org/keywords/elimination-half-life","display_name":"elimination half-life","score":0.7450000047683716},{"id":"https://openalex.org/keywords/tapering","display_name":"tapering","score":0.6200000047683716},{"id":"https://openalex.org/keywords/extended-release-formulation","display_name":"sustained-release formulation","score":0.5699999928474426},{"id":"https://openalex.org/keywords/duloxetine","display_name":"duloxetine","score":0.5899999737739563},{"id":"https://openalex.org/keywords/patient-education","display_name":"patient education","score":0.40400001406669617}],"concepts":[{"id":"https://openalex.org/C2776466888","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine","level":4,"score":0.965904176235199},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.9461748003959656},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.5871318578720093},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5678781270980835},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5417443513870239},{"id":"https://openalex.org/C2909532165","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine Hydrochloride","level":5,"score":0.5357391834259033},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.49307844042778015},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.48879286646842957},{"id":"https://openalex.org/C2777828372","wikidata":"https://www.wikidata.org/wiki/Q408471","display_name":"Paroxetine","level":4,"score":0.48553702235221863},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4071943759918213},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3407188653945923},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2288922809","doi":null,"is_oa":false,"landing_page_url":"https://www.questia.com/library/journal/1G1-435541400/venlafaxine-discontinuation-syndrome-prevention-and","pdf_url":null,"source":{"id":"https://openalex.org/S2764520953","display_name":"Current psychiatry","issn_l":"1537-8276","issn":["1537-8276"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4322696809","host_organization_name":"Frontline Medical Communications","host_organization_lineage":["https://openalex.org/P4322696809"],"host_organization_lineage_names":["Frontline Medical Communications"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Current psychiatry","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2067524987","https://openalex.org/W1967621994","https://openalex.org/W2070949427","https://openalex.org/W148590339","https://openalex.org/W317672763","https://openalex.org/W2586825710","https://openalex.org/W2399292184","https://openalex.org/W2151429019","https://openalex.org/W2102351104","https://openalex.org/W177183128"],"abstract_inverted_index":{"Most":[0,290],"antidepressants":[1,34],"lead":[2],"to":[3,61,74,118,226,247,270,276],"adverse":[4],"discontinuation":[5,30,53,80,168,181,189,201,215,263,308],"symptoms":[6,31,81,169,182,190,216,264,309],"when":[7,217],"they":[8],"are":[9],"abruptly":[10],"stopped":[11],"or":[12,239],"rapidly":[13],"tapered.":[14],"Antidepressants":[15],"with":[16,33,35,84,310,322],"a":[17,36,57,70,112,164,207,248,293,311],"short":[18],"half-life,":[19],"such":[20,279],"as":[21,151,280],"paroxetine":[22],"and":[23,64,92,104,128],"venlafaxine,":[24,171],"can":[25,157,316],"cause":[26],"significantly":[27],"more":[28],"severe":[29,52,307],"compared":[32],"longer":[37,93],"half-life.":[38],"One":[39],"culprit":[40],"in":[41,100,141],"particular":[42],"Among":[43],"serotonin-norepinephrine":[44],"reuptake":[45,251],"inhibitors":[46],"(SNRIs),":[47],"venlafaxine":[48,91,180,194,218,246,275,287,294,315],"is":[49,82,98,149,195,219,224,233,255,282],"notorious":[50],"for":[51,192,214],"symptoms.":[54],"Venlafaxine":[55,97,109],"has":[56,111,124],"half-life":[58,71],"of":[59,72,79,87,90,95,143,167,179,209,289],"3":[60,271,328],"7":[62],"hours,":[63],"its":[65],"active":[66],"metabolite,":[67],"desvenlafaxine,":[68],"possesses":[69],"9":[73],"13":[75],"hours.":[76],"Higher":[77],"frequency":[78],"associated":[83],"the":[85,116,160,222],"use":[86],"higher":[88],"dosages":[89,288],"duration":[94],"treatment.":[96],"available":[99],"immediate":[101],"release":[102,106],"(IR)":[103],"extended":[105],"(XR)":[107],"formulations.":[108],"XR":[110],"slower":[113],"release,":[114],"extending":[115],"time":[117],"peak":[119],"plasma":[120],"concentration":[121],"and,":[122,154],"therefore,":[123],"once":[125],"daily":[126],"dosing":[127],"fewer":[129],"side":[130],"effects;":[131],"however,":[132],"it":[133,259],"offers":[134],"no":[135,172],"substantial":[136],"advantage":[137],"over":[138,268,319],"IR":[139],"formulation":[140],"terms":[142],"diminished":[144],"withdrawal":[145],"effects.":[146],"Desvenlafaxine":[147],"also":[148],"marketed":[150],"an":[152],"antidepressant":[153],"although":[155,258],"one":[156],"speculate":[158],"that":[159],"drug":[161],"would":[162],"have":[163,183,206],"lower":[165],"rate":[166],"than":[170,236],"evidence":[173],"supports":[174],"this":[175],"hypothesis.":[176],"A":[177,229],"range":[178],"been":[184],"reported":[185],"(Table).":[186],"(1)":[187],"Preventing":[188],"Patients":[191],"whom":[193],"prescribed":[196],"should":[197],"be":[198,317],"informed":[199],"about":[200],"symptoms,":[202],"especially":[203],"those":[204],"who":[205,305],"history":[208],"noncompliance.":[210],"Monitor":[211],"patients":[212,291,304],"closely":[213],"stopped--even":[220],"if":[221],"patient":[223],"switched":[225],"another":[227,277],"antidepressant.":[228],"gradual":[230],"dosage":[231,241,295,313,325],"reduction":[232,296,326],"recommended":[234],"rather":[235],"abrupt":[237],"termination":[238],"rapid":[240],"reduction.":[242],"Immediately":[243],"switching":[244],"from":[245,274],"selective":[249],"serotonin":[250],"inhibitor":[252],"(SSRI)":[253],"generally":[254],"not":[256],"recommended,":[257],"could":[260],"alleviate":[261],"some":[262],"(2);":[265],"cross-taper":[266],"medication":[267],"2":[269],"weeks.":[272],"Switching":[273],"SNRI,":[278],"duloxetine,":[281],"less":[283],"well":[284],"studied.":[285],"At":[286],"tolerate":[292],"by":[297],"75":[298],"mg/d,":[299],"at":[300],"1-week":[301],"intervals.":[302],"For":[303],"experience":[306],"minor":[312],"reduction,":[314],"tapered":[318],"10":[320],"months":[321],"approximately":[323],"1%":[324],"every":[327],"days.":[329],"\u2026":[330]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2288922809","counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
